Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CTO Acquires 12,300 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai purchased 12,300 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the transaction, the chief technology officer now owns 33,300 shares of the company’s stock, valued at $280,386. This trade represents a 58.57 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Immunome Trading Up 2.7 %

NASDAQ:IMNM opened at $7.28 on Friday. The stock has a 50 day moving average of $9.56 and a two-hundred day moving average of $11.38. Immunome, Inc. has a 12 month low of $6.94 and a 12 month high of $25.75. The firm has a market cap of $633.00 million, a P/E ratio of -0.90 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. On average, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analyst Weigh In

IMNM has been the topic of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Guggenheim dropped their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Lifesci Capital started coverage on Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, Stephens reiterated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has a consensus rating of “Buy” and a consensus price target of $25.50.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new stake in Immunome during the 4th quarter valued at about $70,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Immunome in the fourth quarter valued at approximately $75,000. AlphaQuest LLC increased its holdings in shares of Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after buying an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Immunome during the fourth quarter worth approximately $95,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.